120 related articles for article (PubMed ID: 1449046)
1. Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus.
Vaag AA; Beck-Nielsen H
Acta Endocrinol (Copenh); 1992 Oct; 127(4):344-50. PubMed ID: 1449046
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
[TBL] [Abstract][Full Text] [Related]
3. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
[TBL] [Abstract][Full Text] [Related]
4. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Eriksson J; Taskinen MR
Diabet Med; 1993 Dec; 10(10):950-7. PubMed ID: 8306591
[TBL] [Abstract][Full Text] [Related]
5. Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Vaag A; Skött P; Damsbo P; Gall MA; Richter EA; Beck-Nielsen H
J Clin Invest; 1991 Oct; 88(4):1282-90. PubMed ID: 1918378
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
[TBL] [Abstract][Full Text] [Related]
7. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
Fulcher GR; Catalano C; Walker M; Farrer M; Thow J; Whately-Smith CR; Alberti KG
Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
[TBL] [Abstract][Full Text] [Related]
8. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
Saloranta C; Taskinen MR; Widen E; Härkönen M; Melander A; Groop L
Diabetes; 1993 Nov; 42(11):1559-66. PubMed ID: 8405695
[TBL] [Abstract][Full Text] [Related]
9. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
[TBL] [Abstract][Full Text] [Related]
10. The effect of an antilipolytic agent (acipimox) on the insulin resistance of lipid and glucose metabolism in hypertriglyceridaemic patients.
Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Taskinen MR
Acta Diabetol; 1994 Apr; 31(1):6-13. PubMed ID: 8043900
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
[TBL] [Abstract][Full Text] [Related]
12. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
Paolisso G; Tagliamonte MR; Rizzo MR; Gualdiero P; Saccomanno F; Gambardella A; Giugliano D; D'Onofrio F; Howard BV
Diabetologia; 1998 Oct; 41(10):1127-32. PubMed ID: 9794097
[TBL] [Abstract][Full Text] [Related]
13. Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients.
Piatti PM; Monti LD; Davis SN; Conti M; Brown MD; Pozza G; Alberti KG
Diabetologia; 1996 Jan; 39(1):103-12. PubMed ID: 8720610
[TBL] [Abstract][Full Text] [Related]
14. Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
Fulcher GR; Walker M; Farrer M; Johnson AS; Alberti KG
Metabolism; 1993 Mar; 42(3):308-14. PubMed ID: 8487648
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure.
Nielsen S; Møller N; Christiansen JS; Jørgensen JO
Diabetes; 2001 Oct; 50(10):2301-8. PubMed ID: 11574412
[TBL] [Abstract][Full Text] [Related]
16. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
Santomauro AT; Boden G; Silva ME; Rocha DM; Santos RF; Ursich MJ; Strassmann PG; Wajchenberg BL
Diabetes; 1999 Sep; 48(9):1836-41. PubMed ID: 10480616
[TBL] [Abstract][Full Text] [Related]
17. The impact of forearm immobilization and acipimox administration on muscle amino acid metabolism and insulin sensitivity in healthy, young volunteers.
Dirks ML; Jameson TSO; Andrews RC; Dunlop MV; Abdelrahman DR; Murton AJ; Wall BT; Stephens FB
Am J Physiol Endocrinol Metab; 2024 Mar; 326(3):E277-E289. PubMed ID: 38231001
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
Makimura H; Stanley TL; Suresh C; De Sousa-Coelho AL; Frontera WR; Syu S; Braun LR; Looby SE; Feldpausch MN; Torriani M; Lee H; Patti ME; Grinspoon SK
J Clin Endocrinol Metab; 2016 Mar; 101(3):1123-33. PubMed ID: 26691888
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
Fulcher GR; Walker M; Catalano C; Agius L; Alberti KG
Diabetes; 1992 Nov; 41(11):1400-8. PubMed ID: 1397716
[TBL] [Abstract][Full Text] [Related]
20. Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
Merovci A; Abdul-Ghani M; Mari A; Solis-Herrera C; Xiong J; Daniele G; Tripathy D; DeFronzo RA
J Clin Endocrinol Metab; 2016 Mar; 101(3):1249-56. PubMed ID: 26765576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]